StreetInsider.com News Articles

Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential

Thu, 22 Oct 2026 16:30:00 -0400

Research collaboration aims to strengthen the science used to assess whether new medicines could be abused, supporting safer drug development and more informed regulatory decisions

BURLINGTON, N.C., Oct. 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the U.S. Food and

Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential

Thu, 22 Oct 2026 16:30:00 -0400

Research collaboration aims to strengthen the science used to assess whether new medicines could be abused, supporting safer drug development and more informed regulatory decisions

BURLINGTON, N.C., Oct. 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the U.S. Food and

Form 8-K LABCORP HOLDINGS INC. For: Oct 20

Wed, 21 Oct 2026 06:51:00 -0400

si-local-file:///var/storage/secattach/20261021/27212739.html

Labcorp (LH) Declares $0.72 Quarterly Dividend; 0.9% Yield

Wed, 21 Oct 2026 06:50:03 -0400

Labcorp (NYSE: LH) declared a quarterly dividend of $0.72 per share, or $2.88 annualized.

The dividend will be payable on December 11, 2026, to stockholders of record on November 24, 2026, with an ex-dividend date of November 23, 2026.

The annual yield on the dividend is 0.9 percent.

For a dividend history and other dividend-related data on Labcorp (LH) click here.

Labcorp Declares Quarterly Dividend

Wed, 21 Oct 2026 06:50:00 -0400

BURLINGTON, N.C., Oct. 21, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 11, 2026, to stockholders of record as of the close of business on November 24, 2026.

Labcorp Declares Quarterly Dividend

Wed, 21 Oct 2026 06:50:00 -0400

Myriad Genetics stock surges on $210M prenatal unit sale

Tue, 20 Oct 2026 11:26:45 -0400

Investing.com -- Myriad Genetics Inc (NASDAQ:MYGN) shares jumped 36% Tuesday following the company's announcement that it will sell its Prenatal Health testing business to Labcorp Holdings Inc (NYSE:LH) for $210 million in cash, plus inventory value at closing.

The transaction includes Myriad's Prequel, Foresight, SneakPeek, and FirstGene tests. The prenatal testing portfolio generated approximately $160 million in revenue over the last twelve months and served over 600,000 patients.

Sam Raha, President and CEO of Myriad Genetics, said the transaction is expected to be accretive to the company's revenue growth and profitability while strengthening the balance sheet

Myriad Genetics stock surges on $210M prenatal unit sale

Tue, 20 Oct 2026 11:26:45 -0400

Sam Raha, President and CEO of Myriad Genetics, said the transaction is expected to be accretive to the company's revenue growth and profitability while strengthening the balance sheet

Myriad Genetics stock surges on $210M prenatal unit sale

Tue, 20 Oct 2026 11:26:45 -0400

Sam Raha, President and CEO of Myriad Genetics, said the transaction is expected to be accretive to the company's revenue growth and profitability while strengthening the balance sheet

Myriad Genetics stock surges on $210M prenatal unit sale

Tue, 20 Oct 2026 11:26:45 -0400

Sam Raha, President and CEO of Myriad Genetics, said the transaction is expected to be accretive to the company's revenue growth and profitability while strengthening the balance sheet

Myriad Genetics to sell prenatal testing unit to Labcorp for $210M

Tue, 20 Oct 2026 09:03:41 -0400

Myriad Genetics (NASDAQ: MYGN) has agreed to sell its Prenatal Health testing business to Labcorp (NYSE: LH) for $210 million in cash, plus the value of inventory at closing, according to a press release issued Oct. 20, 2026.

The business being sold includes the Prequel, Foresight, SneakPeek, and FirstGene tests, which have been used by more than 600,000 patients and thousands of providers over the past twelve months.

Labcorp expects the acquisition to add approximately $160 million in revenue in its first year, be slightly accretive to adjusted earnings in year one, and reach average diagnostics segment margins by the end of

Myriad Genetics to sell prenatal testing unit to Labcorp for $210M

Tue, 20 Oct 2026 09:03:41 -0400

The business being sold includes the Prequel, Foresight, SneakPeek, and FirstGene tests, which have been used by more than 600,000 patients and thousands of providers over the past twelve months.

Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

Tue, 20 Oct 2026 08:30:00 -0400

Transaction to benefit patients through expanded access and support Myriad’s strategic priorities

SALT LAKE CITY and BURLINGTON, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announce they have entered into a definitive agreement for Myriad to sell its Prenatal Health testing business, which includes the Prequel^®, Foresight^®, SneakPeek^®, and FirstGene^® tests, to Labcorp for $210 million in cash, plus the value of the inventory of the Prenatal Health testing

Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

Tue, 20 Oct 2026 08:30:00 -0400

Transaction to benefit patients through expanded access and support Myriad’s strategic priorities

Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

Tue, 20 Oct 2026 08:30:00 -0400

Transaction to benefit patients through expanded access and support Myriad’s strategic priorities

Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp

Tue, 20 Oct 2026 08:30:00 -0400

Transaction to benefit patients through expanded access and support Myriad’s strategic priorities

Opko Health stock soars on $722M BioReference asset sale

Thu, 15 Oct 2026 09:53:22 -0400

Investing.com -- Opko Health Inc (NASDAQ:OPK) shares surged 20% in premarket trading Thursday after Labcorp Holdings Inc (NYSE:LH) agreed to acquire select assets of BioReference Health for $722 million in cash.

Labcorp will acquire BioReference Health's laboratory testing businesses focused on clinical and women's health testing services, urology, corrections and certain operational assets, including over 80 patient service centers. The purchase price includes up to an additional $150 million in an earnout based on revenue from the 4Kscore Test.

The transaction includes BioReference Health's proprietary 4Kscore Test, an FDA-approved blood test that helps predict the likelihood

Opko Health stock soars on $722M BioReference asset sale

Thu, 15 Oct 2026 09:53:22 -0400

The transaction includes BioReference Health's proprietary 4Kscore Test, an FDA-approved blood test that helps predict the likelihood

Opko Health stock soars on $722M BioReference asset sale

Thu, 15 Oct 2026 09:53:22 -0400

The transaction includes BioReference Health's proprietary 4Kscore Test, an FDA-approved blood test that helps predict the likelihood

Opko Health stock soars on $722M BioReference asset sale

Thu, 15 Oct 2026 09:53:22 -0400

The transaction includes BioReference Health's proprietary 4Kscore Test, an FDA-approved blood test that helps predict the likelihood

Labcorp to buy BioReference Health assets from OPKO for $722M

Thu, 15 Oct 2026 07:30:44 -0400

Labcorp (NYSE: LH) has agreed to acquire select assets of BioReference Health, LLC, a wholly owned subsidiary of OPKO Health (Nasdaq: OPK), for $722 million in cash at closing, with up to an additional $150 million in an earnout tied to revenue from the 4Kscore Test.

Under the terms of the deal, Labcorp will acquire BioReference Health's clinical and women's health testing businesses, urology, corrections services, and certain operational assets, including more than 80 patient service centers. The transaction also includes BioReference Health's proprietary 4Kscore Test, an FDA-approved blood test used to assess the likelihood of aggressive prostate cancer prior to

Labcorp to buy BioReference Health assets from OPKO for $722M

Thu, 15 Oct 2026 07:30:44 -0400

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Thu, 15 Oct 2026 07:30:00 -0400

Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide

BURLINGTON, N.C. and MIAMI, Fla., Oct. 15, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK),

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Thu, 15 Oct 2026 07:30:00 -0400

Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide

BURLINGTON, N.C. and MIAMI, Fla., Oct. 15, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK),

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Thu, 15 Oct 2026 07:30:00 -0400

Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide

BURLINGTON, N.C. and MIAMI, Fla., Oct. 15, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK),